DURECT (NASDAQ: DRRX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
DURECT Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
DURECT Company Info
The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.
News & Analysis
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
The biotech becomes a COVID-19 play and benefits from a competitor's failure.
Seven biotechs led the way.
The biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.
Investors jump in ahead of a binary event.
Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
Investors bid up the share price after the company received some bullish praise from a Wall Street pro.
Durect gets some much-needed cash after its partner Indivior received a positive nod for its schizophrenia drug.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
DRRX earnings call for the period ending September 30, 2020.
DRRX earnings call for the period ending June 30, 2020.
DRRX earnings call for the period ending March 31, 2020.
DRRX earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.